| |
Warner Chilcott buy may be Actavis' best takeover defense
Fri 1:12 pm ET (at Reuters)
By Jessica Toonkel NEW YORK (Reuters) - Generic drugmaker Actavis (ACT.N: Quote , Profile , Research , Stock Buzz ), the subject of intense takeover speculation, may have found its best defense: a potential ...
|
|
Top-Ranked Analysts
|
Provided by StarMine
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 919B | | Price
/ Earnings: | 41.8 | | Price
/ Book: | -6.0 | | Net
Profit Margin (mrq): | 5.1% | | Price
To Free Cash Flow (mrq): | -7.9 | | Return
on Equity: | 8.0% | | Total
Debt / Equity: | 50.8 | | Dividend
Yield: | 0.1% |
|